Psyence Biomedical Ltd. (PBM)

NCM – Real Time Price. Currency in USD

2.97

+0.25 (9.19%)

At close: Jun 26, 2026, 4:00 PM EDT

2.90

-0.07 (-2.36%)

After-hours: Jun 26, 2026, 7:36 PM EDT

16.06.2026

Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform

MINNEAPOLIS--(BUSINESS WIRE)--Tredium Solutions, a provider of pharmacy benefit management (PBM) technologies, has been selected to support the administration of Scripius' commercial, Medicare, and Medicaid pharmacy benefit programs. Through this collaboration, Tredium will provide its claims platform to support accurate and reliable processing for Scripius and the customers it serves. Scripius empowers health plans, health systems, and self-funded employers to better manage rising pharmacy cos.

15.05.2026

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives.

23.04.2026

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network

20.04.2026

PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story

Over the weekend, President Donald Trump issued an executive order aimed at speeding psychedelic drug reviews, while also backing faster ibogaine research with a reported $50 million commitment, helping ignite premarket buying across the space and lowering perceived regulatory risk for companies tied to psychedelic development.

20.04.2026

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain

17.04.2026

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourced supply Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourced supply

08.04.2026

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the expansion of its clinical site network in Australia from three to five sites supporting its ongoing clinical activities.

Videos

No Data

There is no data to display

Press releases

16.06.2026

Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform

15.05.2026

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

23.04.2026

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

20.04.2026

Psyence Biomedical Ltd. (PBM)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Psyence Biomedical Ltd. (PBM)

Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

Videos

No Data

Press releases

Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

Videos

No Data

Press releases

Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

Search stocks

Psyence Biomedical Ltd. (PBM)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Psyence Biomedical Ltd. (PBM)

Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

Videos

No Data

Press releases

Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

Videos

No Data

Press releases

Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source